Overall rank by patents
#29,039
Across all tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 5 technology areas, active 2015–2017. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G06T (IMAGE DATA PROCESSING OR GENERATION, IN GENERAL).
The verdict
Impac holds 9 US patents across 5 technology areas, rank #29,039 of 50,000 tracked assignees.
Impac Medical Systems, Inc. has been granted 9 US utility patents between 2015 and 2017, placing Impac Medical Systems, Inc. at rank #29,039 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.3 claims per patent with primary concentration in G06T (IMAGE DATA PROCESSING OR GENERATION, IN GENERAL). As a US Corporation, Impac Medical Systems, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Impac sits between Imba—institut Für Molekulare Biotechnologie Gmbh (9 patents, rank #29,035) and Inbios International, Inc. (9 patents, rank #29,043) - the closest US assignees by grant volume. The composite Innovation Score of 29.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 9 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Impac Medical Systems, Inc.'s 23.3 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Impac Medical Systems, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
IMBA—INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
9 patents
IMEDICOM CO., LTD.
9 patents
IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
9 patents
IMMUNOQURE AG
9 patents
IMSOL CORP.
9 patents
IN Ingredients, Inc.
9 patents
IN-TECH ENTERPRISE LTD.
9 patents
INBIOS INTERNATIONAL, INC.
9 patents
IMPAC Medical Systems, Inc.
9 patents
What this shows Impac holds 9 patents at rank #29,039, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #29,039 in granted patent volume.
Other assignees with the most granted patents in Impac's primary technology class.
Impac's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
30 Top 68% higher than 32% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 22.2% |
| 2016 | 3 | 33.3% |
| 2017 | 4 | 44.4% |
Top 5 of 5 technology areas
Overall rank by patents
#29,039
Across all tracked assignees
29.9 out of 100
How to use this portfolio
Impac's 9 grants land it in the top 68% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.